Hyqvia (Human Normal Immunoglobulin, Hyaluronidase (Human Recombinant))

The human normal immunoglobulin component provides a broad spectrum of IgG antibodies that can neutralize pathogens, offering passive immunity. Recombinant hyaluronidase temporarily breaks down hyaluronan in the subcutaneous tissue, increasing tissue permeability and allowing a larger volume of immunoglobulin to be infused efficiently.

The dosage of Hyqvia is individualized and determined by the prescribing healthcare professional based on the patient’s weight, IgG trough levels, and clinical response. Patients should follow the specific dosing instructions provided by their physician and the product’s prescribing information.

The safety of Hyqvia in pregnancy and lactation has not been fully established. Healthcare providers should weigh the potential benefits against any possible risks and consider alternative therapies if appropriate. Pregnant or nursing patients should discuss their specific situation with a qualified medical professional.

To place an order, submit an enquiry on the Hyqvia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Hyqvia combines IgG with recombinant hyaluronidase, enabling subcutaneous infusion of larger volumes compared with conventional subcutaneous immunoglobulin products. This can reduce infusion frequency and improve patient convenience, while maintaining comparable efficacy and safety profiles to other IgG replacement therapies administered intravenously or subcutaneously.

Hyqvia must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Proper cold‑chain logistics are essential to maintain product stability until administration.

Hyqvia is given as a subcutaneous infusion using a dedicated infusion set. The hyaluronidase component is administered first to increase tissue permeability, followed by the immunoglobulin solution. Infusion rates and volumes are set by the prescribing clinician and administered in a clinical setting or at home under supervision.

Serious risks include severe allergic reactions such as anaphylaxis, thrombotic events like deep vein thrombosis, and renal impairment or acute kidney injury. Patients should be monitored closely for signs of these reactions during and after infusion, and immediate medical attention should be sought if they occur.

Hyqvia is contraindicated in individuals with a known hypersensitivity to human immunoglobulin, hyaluronidase, or any excipients in the formulation. Patients with severe IgA deficiency who have anti‑IgA antibodies should avoid use due to the heightened risk of severe reactions.